Clinical And Imageological Features Of Lung Squamous Cell Carcinoma With EGFR Mutations

References

• Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32(4):669–692. doi:10.1016/j.ccm.2011.08.00522054879
   PubMed Web of Science ®Google Scholar
• Klughammer B, Brugger W, Cappuzzo F, et al. Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations. J Thorac Oncol. 2016;11(4):545–555. doi:10.1016/j.jtho.2015.12.10726773740
   PubMed Web of Science ®Google Scholar
• Gandara DR, Hammerman PS, Sos ML, Lara PN Jr., Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015;21(10):2236–2243. doi:10.1158/1078-0432.CCR-14-303925979930
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Khuder SA, Mutgi AB. Effect of smoking cessation on major histologic types of lung cancer. Chest. 2001;120(5):1577–1583. doi:10.1378/chest.120.5.157711713137
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742. doi:10.1016/S1470-2045(11)70184-X21783417
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–967. doi:10.1056/NEJMoa090455419692684
   PubMed Web of Science ®Google Scholar
• Zhang GC, Lin JY, Wang Z, et al. Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients. Clin Oncol (R Coll Radiol). 2007;19(7):499–506. doi:10.1016/j.clon.2007.04.00617537621
   PubMed Web of Science ®Google Scholar
• Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–162. doi:10.1097/JTO.000000000000003324419411
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–525. doi:10.1038/nature1140422960745
   PubMed Web of Science ®Google Scholar
• Einhorn LH. First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? J Clin Oncol. 2008;26(21):3485–3486. doi:10.1200/JCO.2008.17.205618506022
   PubMed Web of Science ®Google Scholar
• Tagliamento M, Genova C, Rijavec E, et al. Afatinib and erlotinib in the treatment of squamous-cell lung cancer. Expert Opin Pharmacother. 2018;19(18):2055–2062. doi:10.1080/14656566.2018.154059130392436
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500. doi:10.1126/science.109931415118125
   PubMed Web of Science ®Google Scholar
• Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64(24):8919–8923. doi:10.1158/0008-5472.CAN-04-281815604253
   PubMed Web of Science ®Google Scholar
• Liu Y, Kim J, Balagurunathan Y, et al. Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. Clin Lung Cancer. 2016;17(5):441–448 e446. doi:10.1016/j.cllc.2016.02.00127017476
   PubMed Web of Science ®Google Scholar
• Rizzo S, Petrella F, Buscarino V, et al. CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol. 2016;26(1):32–42. doi:10.1007/s00330-015-3814-025956936
   PubMed Web of Science ®Google Scholar
• Yang Z, Yang N, Ou Q, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018;24(13):3097–3107. doi:10.1158/1078-0432.CCR-17-231029506987
   PubMed Web of Science ®Google Scholar
• Wang X, Gao Y, Wang B, et al. Analytic and clinical validation of an ultrasensitive, quantitative polymerase chain reaction assay for EGFR mutation analysis with circulating tumor DNA. Arch Pathol Lab Med. 2017;141(7):978–984. doi:10.5858/arpa.2016-0083-OA28537806
   PubMed Web of Science ®Google Scholar
• Pan Y, Zhang Y, Li Y, et al. Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma. Ann Surg Oncol. 2014;21(Suppl 4):S490–S496. doi:10.1245/s10434-013-3452-124419753
   PubMedGoogle Scholar
• Calio A, Nottegar A, Gilioli E, et al. ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. J Thorac Oncol. 2014;9(5):729–732. doi:10.1097/JTO.000000000000010924722159
   PubMed Web of Science ®Google Scholar
• Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25(3):405–415. doi:10.1038/modpathol.2011.17322056955
   PubMed Web of Science ®Google Scholar
• Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011;24(10):1348–1359. doi:10.1038/modpathol.2011.9221623384
   PubMed Web of Science ®Google Scholar
• Lu S, Li W, Zhou C, et al. Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. Onco Targets Ther. 2018;11:8565–8573. doi:10.2147/OTT.S16150630573970
   PubMed Web of Science ®Google Scholar
• Soria J-C, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015;16(8):897–907. doi:10.1016/S1470-2045(15)00006-626156651
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2006;118(2):257–262. doi:10.1002/ijc.2149616231326
   PubMed Web of Science ®Google Scholar
• Park SH, Ha SY, Lee JI, et al. Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. J Korean Med Sci. 2009;24(3):448–452. doi:10.3346/jkms.2009.24.3.44819543508
   PubMed Web of Science ®Google Scholar
• Jia XL, Chen G. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. Lung Cancer. 2011;74(3):396–400. doi:10.1016/j.lungcan.2011.04.00521592614
   PubMed Web of Science ®Google Scholar
• Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17(11):637–658. doi:10.1038/nrc.2017.8429068003
   PubMed Web of Science ®Google Scholar
• Makoto Maemondo MD Ph.D., Akira Inoue MD Ph.D., Kunihiko Kobayashi MD Ph.D.; for the North-East Japan Study Group, et al. Gefitinib or chemotherapy for non–smallcell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388. doi:10.1056/NEJMoa090953020573926
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi:10.1056/NEJMoa081069919692680
   PubMed Web of Science ®Google Scholar
• O’Kane GM, Bradbury PA, Feld R, et al. Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer. 2017;109:137–144. doi:10.1016/j.lungcan.2017.04.01628577943
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhu L, Zhang J. Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients. BMC Cancer. 2015;15:88. doi:10.1186/s12885-015-1584-325886585
   PubMed Web of Science ®Google Scholar
• Monnet I, Audigier-Valette C, Girard N, et al. Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: results of the PEPiTA observational study. Lung Cancer. 2016;98:84–90. doi:10.1016/j.lungcan.2016.05.01627393512
   PubMed Web of Science ®Google Scholar
• Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005;353(2):133–144. doi:10.1056/NEJMoa05073616014883
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521–529. doi:10.1016/S1470-2045(10)70112-120493771
   PubMed Web of Science ®Google Scholar
• Reck M, van Zandwijk N, Gridelli C, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol. 2010;5(10):1616–1622. doi:10.1097/JTO.0b013e3181f1c7b020736854
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13(3):300–308. doi:10.1016/S1470-2045(11)70385-022277837
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Ando M, Asami K, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol. 2014;32(18):1902–1908. doi:10.1200/JCO.2013.52.469424841974
   PubMed Web of Science ®Google Scholar
• Taniguchi Y, Matsumoto Y, Furukawa R, Ohara S, Usui K. The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations. Int J Clin Oncol. 2018;23(3):452–457. doi:10.1007/s10147-017-1233-829446042
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018;13(3):323–358. doi:10.1016/j.jtho.2017.12.00129396253
   PubMed Web of Science ®Google Scholar